The safety of gadolinium-based contrast agents for MRI continues to generate much controversy and discussion. As both a radiologist and a lawyer, Dr. Alexander Radbruch, JD, is well-placed to comment on the most significant recent developments in gadolinium retention in the brain, how best to use these agents, and how radiologists and manufacturers can help to avoid being sued.
The safety of gadolinium-based contrast agents for MRI continues to generate much controversy and discussion. As both a radiologist and a lawyer, Dr. Alexander Radbruch, JD, is well-placed to comment on the most significant recent developments on gadolinium retention in the brain, how best to use these agents, and how radiologists and manufacturers can help to avoid being sued.Video from ECR 2019: Alexander Radbruch on gadolinium debate
Feb 28, 2019
Latest in PACS/VNA
PACS workstations add to power consumption in radiology departments
September 23, 2026
AdvaHealth gets FDA nod for diagnostic viewer
September 22, 2026
Candelis wins Health Canada approval for StreamVue
September 9, 2026
Novarad releases NovaPACS update
August 28, 2026


















